1 Clinical performance validation of the STANDARD G6PD Test: A multi-

2 country pooled analysis

- 3 Wondimagegn Adissu^{1,2}, Marcelo Brito^{3,4}, Eduardo Garbin⁵, Marcela Macedo⁵, Wuelton Monteiro^{3,4},
- 4 Sandip Mukherjee⁶, Jane Myburg⁷, Mohammad Shafiul Alam⁸, Germana Bancone^{9, 10}, Pooja Bansil¹¹,
- 5 Sampa Pal¹¹, Abhijit Sharma¹¹, Stephanie Zobrist¹¹, Andrew Bryan¹², Cindy S Chu^{9,10}, Santasabuj Das⁶,
- 6 Gonzalo J Domingo¹¹, Amanda Hann⁷, James Kublin^{12,13}, Marcus VG Lacerda^{3,4,14}, Mark Layton⁷,
- 7 Benedikt Ley¹⁵, Sean C Murphy^{16,17}, Francois Nosten^{9,10}, Dhélio Pereira^{5,18}, Ric N Price^{10,15}, Arunansu
- 8 Talukdar¹⁹, Daniel Yilma^{2,20}, Emily Gerth-Guyette^{11*}

9 Affiliations:

- 10 1. School of Medical Laboratory Sciences, Jimma University, Jimma, Ethiopia 11 2. Clinical Trial Unit, Jimma University, Jimma, Ethiopia 3. Fundação de Medicina Tropical Dr Heitor Vieira Dourado (FMT-HVD), Manaus, Amazonas, 12 13 Brazil 14 4. Universidade do Estado do Amazonas, Manaus, Amazonas, Brazil 5. Centro de Pesquisa Em Medicina Tropical (CEPEM), Porto Velho, Rondônia, Brazil 15 16 6. National Institute of Cholera and Enteric Diseases, Kolkata, India 17 7. Special Haematology Laboratory, Hammersmith Hospital, London, United Kingdom 18 8. Infectious Diseases Division, International Centre for Diarrheal Diseases Research, Bangladesh 19 (icddr,b), Mohakhali, Dhaka, Bangladesh 20 9. Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of 21 Tropical Medicine, Mahidol University, P.O. Box 46, 68/31 Bann Tung Road, Mae Sot, 63110, 22 Thailand. 23 10. Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of 24 Oxford, Oxford, United Kingdom 11. Diagnostics, PATH, Seattle, Washington, United States of America 25 12. Departments of Laboratory Medicine and Microbiology, University of Washington School of 26
- 27 Medicine, Seattle, Washington, United States of America
- 13. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle,
 Washington, United States of America
- 30 14. Instituto Leônidas & Maria Deane (ILMD), Fiocruz, Manaus, Amazonas, Brazil
- 31 15. Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin
 32 University, Darwin, Australia

It is made available under a CC-BY-NC 4.0 International license .

- 33 16. Department of Laboratory Medicine and Pathology, University of Washington, Seattle,
- 34 Washington, United States of America
- 35 17. Center for Emerging and Reemerging Infectious Diseases, University of Washington, Seattle,
- 36 Washington, United States of America
- 37 18. Universidade Federal de Rondônia (UNIR), Porto Velho, Rondônia, Brazil
- 38 19. Kolkata Medical College Hospital, India
- 39 20. Department of Internal Medicine, Jimma University, Jimma, Ethiopia
- 40 **Corresponding author:** Emily Gerth-Guyette

41

It is made available under a CC-BY-NC 4.0 International license .

42 Abstract

- 43 Introduction: Screening for G6PD deficiency can inform disease management including malaria.
- 44 Treatment with the antimalarial drugs primaquine and tafenoquine can be guided by point-of-care testing
- 45 for G6PD deficiency.

46 Methods and Findings: Data from similar clinical studies evaluating the performance of the

47 STANDARDTM G6PD Test (SD Biosensor, South Korea) conducted in Bangladesh, Brazil, Ethiopia,

48 India, Thailand, the United Kingdom, and the United States were pooled. Test performance was assessed

49 in a retrospective analysis on capillary and venous specimens. All study sites used spectrophotometry for

- 50 reference G6PD testing, and either the HemoCue or complete blood count for reference hemoglobin
- 51 measurement.

52 The sensitivity of the STANDARDTM G6PD Test using the manufacturer thresholds for G6PD deficient

and intermediate cases in capillary specimens from 4212 study participants was 100% (95% Confidence

54 Interval (CI): 97.5%–100%) for G6PD deficient cases with <30% activity and 77% (95% CI 66.8%–

55 85.4%) for females with intermediate activity between 30%–70%. Specificity was 98.1% (95% CI

56 97.6%–98.5%) and 92.8% (95% CI 91.6%–93.9%) for G6PD deficient individuals and intermediate

57 females, respectively. The majority (12/20) of G6PD intermediate females with false normal results had

58 activity levels >60% on the reference assay. Negative predictive values for females with G6PD activity

59 >60% was 99.6% (95% CI 99.1%–99.8%) on capillary specimens. Test sensitivity among 396 P. vivax

60 malaria cases was 100% (69.2%–100.0%) for both deficient and intermediate cases. In the study

61 population, a high proportion of those classified as G6PD deficient or intermediate resulted from true

62 normal cases. Despite this, the majority cases would receive the correct medication and no true G6PD

63 deficient cases would be treated inappropriately.

64 **Conclusions:** The STANDARD G6PD Test enables safe access to drugs which are contraindicated for

65 individuals with G6PD deficiency. Operational considerations will inform test uptake in specific settings.

66 Keywords: G6PD enzyme activity, malaria, *Plasmodium vivax*, diagnostic performance

It is made available under a CC-BY-NC 4.0 International license .

67 Introduction

68 The glucose-6-phosphate dehydrogenase (G6PD) enzyme plays an essential role in the protection of red 69 blood cells against damage from oxidative stress. This enzyme is one of the most polymorphic in the human genome, leading to many mutations resulting in the enzymopathy G6PD deficiency.¹ G6PD 70 deficiency is one of the most common human genetic disorder affecting an estimated 500 million people 71 72 worldwide.¹ The red blood cells of individuals with this condition have decreased G6PD enzyme activity 73 and are more susceptible to hemolysis as a result of an oxidative challenge. Common oxidative challenges include from foods such as fava beans.² infections such as SARS-CoV-2 infection^{3,4} and typhoid, and 74 medications such as rasburicase⁵ and 8-aminoquinoline-based anti-malaria drugs used for radical cure 75 treatment of *Plasmodium vivax* malaria (e.g., primaguine and tafenoquine).^{6,7} G6PD deficiency is also a 76 77 strong predictor of pathologic neonatal jaundice and potential for life-threatening kernicterus in newborns.⁸⁻¹⁰ 78

79 Until recently, diagnosis of G6PD deficiency has primarily relied on moderate to high complexity

80 laboratory assays. In practice, the implementation of such tests has been challenging as described in

81 recent publications from the College of American Pathologists.^{11,12} More recently, point-of-care (POC)

tests for G6PD deficiency are emerging, providing opportunities to expand testing to populations without

83 access to laboratory-based assays.¹³ Such tests are particularly important in the context of malaria case

84 management, given the limited infrastructure in settings where malaria patients typically seek care. At a

global level, the World Health Organization recommends G6PD testing prior to the administration of

86 radical cure treatments for *P. vivax* malaria.¹⁴ However, among malaria-endemic countries, policies and

87 practices related to G6PD testing and radical cure implementation vary significantly, based in part on the

⁸⁸ underlying epidemiology of G6PD deficiency as well as barriers to access and adoption.¹⁵

89 POC tests for G6PD deficiency include both qualitative rapid tests, as well as quantitative biosensor tests

90 that provide numeric results of patients' G6PD activity levels. Two qualitative tests have shown promise

91 under laboratory conditions, but have limitations in field conditions, including challenges with

92 temperature correction and the inability to identify females with intermediate G6PD activity arising from

93 a heterozygous $g6pd_{normal}/g6pd_{deficient}$ genotype.^{16–18} The STANDARD G6PD Test (SD Biosensor,

94 Republic of Korea) is a quantitative enzymatic colorimetric assay intended to aid in the detection of

95 G6PD deficiency at the POC. The test measures G6PD enzyme activity normalized by hemoglobin (Hb)

96 (U/g Hb) and total-hemoglobin concentration (g/dL) on $10 \mu l$ of capillary or venous blood samples.

97 Results are provided within two minutes on a portable, handheld analyzer and used to classify individuals

as G6PD normal, intermediate, or deficient according to the manufacturer's recommended thresholds.

It is made available under a CC-BY-NC 4.0 International license .

- 99 This classification can be used to inform clinical decision-making, particularly as it relates to priority
- 100 applications, such as malaria case management.
- 101 Cross-sectional diagnostic accuracy studies have been conducted in a wide range of settings and
- 102 locations, to evaluate the performance of the STANDARD G6PD Test.^{19–22} Pooling data from these
- 103 studies allows for a robust diagnostic performance analysis across diverse populations representative of
- 104 multiple contexts and use cases for POC G6PD testing. Our aim was to 1) present these data for the
- 105 STANDARD G6PD Test, 2) explore how a common set of thresholds to classify G6PD deficient or
- 106 intermediate individuals with POC testing can be applied across populations, and 3) consider the
- 107 implications of the test performance on 8-aminoquinoline malaria treatment regimens.

108 Materials and Methods

109 Data were included from similar cross-sectional diagnostic accuracy studies conducted in seven countries:

- 110 Bangladesh,²¹ Brazil,²⁰ Ethiopia (unpublished), India (unpublished), Thailand,¹⁹ the United Kingdom,²²
- 111 and the United States^{19,22} (Supplementary Table 1). Collectively, these studies span a varied range of
- 112 underlying G6PD epidemiology and malaria incidence. The primary objective of all studies was to
- evaluate the performance of the STANDARD G6PD Test for its ability to identify G6PD normal,
- 114 intermediate, and deficient individuals, and to evaluate the test's ability to measure hemoglobin
- 115 concentration. The performance of the STANDARD G6PD Test on capillary and/or venous specimens
- 116 was compared to G6PD reference values normalized by hemoglobin from venous specimens tested with a
- 117 spectrophotometer. Only one study (Thailand) used frozen venous specimens.¹⁹ The performance of the
- 118 STANDARD G6PD Test in the measurement of hemoglobin concentration was also compared to a
- 119 complete blood count from automated hematology analyzers where available, and/or to results from
- 120 venous specimens on the HemoCue 201+ system.

121 Ethical considerations and study populations

- 122 All studies involving human subjects were reviewed by relevant ethics committees (Supplementary Table
- 123 1) and written informed consent to participate was obtained for all participants. Varying recruitment
- 124 methods appropriate to each site were employed to ensure study populations that were both representative
- 125 of intended use settings—including malaria-endemic settings and blood donation centers—as well as of
- 126 G6PD activity levels across the dynamic range (Supplementary Table 1).
- 127 Testing
- 128 Supplementary Figure 1 summarizes the tests and overall workflow of the included studies.

It is made available under a CC-BY-NC 4.0 International license .

129 STANDARD G6PD Test. The STANDARD G6PD Test was performed in all studies on non-

- 130 anticoagulated capillary and/or venous K₂EDTA whole blood as per the manufacturer's instructions. In
- 131 addition to the analyzer, test components include disposable test strips (Test Devices), disposable blood
- 132 transfer tubes (Ezi Tubes+), extraction buffer vials, and a lot-specific code chip used for calibration. For
- testing on capillary specimens, 10 μl of blood was collected via fingerprick using a disposable Ezi Tube+
- and mixed with the extraction buffer. Next, a second, clean Ezi Tube+ was used to transfer 10 µl of the
- 135 mixed specimen to the Test Device, which is inserted into the analyzer. When run on venous specimens,
- 136 $10 \,\mu$ l of blood was transferred to the buffer solution using either a professional pipette^{20–22} or the Ezi
- 137 Tube+ sample collector.^{19,22} After two minutes, the test reports quantitative measurements of G6PD
- 138 activity in U/g Hb and hemoglobin (g/dL). The manufacturer's recommended G6PD activity thresholds
- 139 were applied to determine G6PD status based on the quantitative test result: 4.0 U/g Hb and 6.0 U/g Hb
- 140 for G6PD deficient (\leq 30% activity) and intermediate (\leq 70% activity), respectively.

141 <u>Reference G6PD testing.</u> In all studies, spectrophotometry was used as the reference assay on venous

142 K₂EDTA whole blood, using a temperature-regulated instrument. Either the Pointe Scientific (Canton,

143 MI, catalog number G7583) or the Trinity Biotech (Bray, Ireland) G6PD reagent kits were used. All

144 G6PD activity results were normalized for hemoglobin concentration and are presented in U/g Hb.

145 <u>Hemoglobin measurement.</u> Hemoglobin was measured according to the following methods:

- Complete blood count (CBC). In the Bangladesh, Brazil, Ethiopia, India, Thailand, and US (2021)
 studies in Pennsylvania and Washington,^{19–22} total hemoglobin concentration (g/dL) was
 determined using a CBC on an automated hematology analyzer. This measurement served as the
 reference method for the measurement of Hb concentration and was used to normalize the
 reference assay for G6PD activity.
- *HemoCue 201*+. With the exception of the Bangladesh and Thailand studies, the HemoCue Hb
- 152 201+ System was also performed on non-anticoagulated capillary blood and/or venous K₂EDTA
- blood as a comparative measure of hemoglobin concentration in g/dL according to the
- 154 manufacturer instructions. For studies where CBC was not available, the HemoCue 201+
- 155 measurement was used to normalize the reference assay for G6PD activity.
- Malaria testing. In three studies, the malaria status of participants was assessed by the standard method at
 each site—either microscopy (Brazil) or rapid diagnostic test (Ethiopia and India).
- 158 **Contrived specimen study**

It is made available under a CC-BY-NC 4.0 International license .

Lastly, data are also presented for a contrived specimen study²² that included a panel of 90 specimens

160 spanning critical G6PD activity thresholds developed using heat abrogation and following a method

161 adapted from the UK National External Quality Assurance Services G6PD scheme.²³ Five contrived

162 specimens representing a broad hemoglobin concentration range were also developed using plasma-level

adjustment. These 95 samples underwent blinded testing with the STANDARD G6PD Test and reference

164 assay.

165 Statistical methods

166 Due to the observed inter-laboratory variability of the G6PD reference assay,^{11,22} absolute G6PD values

167 were normalized for each laboratory conducting the reference assay in each study.^{24–26} Reference G6PD

168 activity values were expressed as the percentage of each site's adjusted male median (AMM). For the

169 majority of studies, the AMM was calculated from a subset of randomly selected males (n=36) with

170 normal G6PD status as determined by each laboratory's reference range. These 36 males were

subsequently excluded from the analytical population for the performance analysis. In the UK study, 39

172 males were used to calculate the AMM. In the Bangladesh study, the AMM was calculated from the

173 median activity of all known G6PD normal participants. For the Thai study, the AMM was calculated as

174 described in Domingo et al. (2013),²⁷ wherein all males with reference G6PD activity $\leq 10\%$ of the male

175 median were excluded, and a new median activity was determined and used to normalize the reference

176 data. A Kruskal Wallis test was used to compare medians between groups. Next, categorical thresholds

177 were used to classify G6PD deficient cases (males and females with \leq 30% activity), and females with

178 intermediate activity (> 30% and \leq 70% activity).

179 Using pooled data from across all included studies, receiver operating characteristic (ROC) curves were

180 generated to assess the ability of the test to discriminate G6PD deficient males and females, G6PD

181 intermediate females, and G6PD normal males and females.

182 The pooled performance of the STANDARD G6PD Test against the spectrophotometric reference test for

183 each specimen type was determined by calculating the test's sensitivity and specificity, and 95%

184 confidence interval (CIs) to diagnose individuals G6PD status at the 30% and 70% thresholds.²⁷ For the

185 purposes of this analysis, G6PD deficient and intermediate results by the reference assay were considered

as true "positive", and G6PD normal results were considered as true "negatives." Overall agreement

187 between the STANDARD G6PD Test and reference assay in the classification of normal, intermediate,

and deficient G6PD activity levels was calculated and Kappa coefficients were determined at the same

189 thresholds. Agreement was assessed for the STANDARD G6PD Test's T-Hb measurement against the

It is made available under a CC-BY-NC 4.0 International license .

- 190 reference CBC assay results where available, using clinically-relevant thresholds for anemia established
- 191 by the World Health Organization (WHO) (Supplementary Table 2).²⁸

192 All statistical analyses were performed using Stata® 15.0 (StataCorp, College Station, TX).

193 To explore the implications of these results for malaria case management, the eligibility of the pooled

- 194 study population for radical cure treatment regimens was considered. These eligibility criteria were based
- 195 on the WHO recommendations regarding administration of primaquine for preventing relapse¹⁴ as well as
- 196 the product label for tafenoquine (Supplementary Table 3). Across the study population, G6PD
- 197 classification by the reference assay was compared to G6PD classification by the SD Biosensor test. Next,
- 198 theoretical treatment eligibility among the study population was calculated based on the results of both
- 199 the reference assay and the STANDARD G6PD Test, with the former considered as the gold standard and
- 200 true discriminating test while the latter was considered as the test that would determine treatment status.
- 201 Based on the concordance or discordance between methods, participants were considered as either
- 202 correctly or incorrectly receiving or being excluded from the recommended treatment algorithm outcome.
- 203 Results are presented separately for two different treatment algorithms: 1) primaquine only, and 2)
- tafenoquine and primaquine, with those who were considered ineligible for tafenoquine then considered
- 205 for primaquine eligibility. No other treatment eligibility criteria (e.g., age, pregnancy, anemia status) were
- 206 considered as part of the calculation.

207 **Results**

- 208 Data from 4,212 capillary specimens and 4,844 venous specimens were included in the analysis (Table 1).
- 209 The overall population was split evenly between males and females. The majority of participants with
- available data had either no or mild anemia. A total of 550 patients with confirmed malaria were included
- in the analysis.

212 **G6PD activity distribution**

- 213 The site-specific AMMs are reported in Supplementary Table 4. Study-specific median G6PD values and
- 214 interquartile ranges (IQRs) for all normal males in the analytical populations on both the reference assay
- and the STANDARD G6PD Test on capillary and venous specimens are presented in Figure 1 and
- 216 Supplementary Table 5. On the reference assay, the G6PD median ranged from 6.8 U/g Hb to 11.9 U/g
- 217 Hb, as compared to 6.7 U/g Hb to 11.3 U/g Hb on the STANDARD G6PD Test. Overall, the G6PD
- 218 median of the STANDARD G6PD Test was within a 1.5 U/g Hb range, with the exception of one of the
- 219 US studies.¹⁹ No correlation was observed between the reference assay G6PD normal male median and
- that of the STANDARD G6PD test across studies (data not shown). In Brazil and India, the study

It is made available under a CC-BY-NC 4.0 International license .

221 population was recruited from those seeking care for malaria (Supplementary Table 1) and included a

222 sufficient number of *P. vivax* cases among normal males. There was no significant difference in the AMM

- between malaria negative males and *P. vivax* positive males (Table 2). Among G6PD normal males, the
- median G6PD activity was significantly lower for *P. vivax* positive males compared to malaria negative
- 225 males at the Kolkata, India, site, but not at the Porto Velho, Brazil, site.
- Based on the 30% and 70% activity thresholds, data were available for 266 G6PD deficient, 233 G6PD
- 227 intermediate, and 4,520 G6PD normal specimens (Table 1). The pooled prevalence for G6PD deficient
- and intermediate cases in the capillary sample analytical population was 3.4% and 2.1%, respectively
- 229 (Supplementary Table 6). The pooled prevalence for G6PD deficient and intermediate cases in the venous
- blood analytical population was 5.4% and 4.7%, respectively (Supplementary Table 6). Supplementary
- Figure 2 presents the distribution of G6PD activities in the study population according to the reference
- assay and the STANDARD G6PD Test for both males and females.

233 Pooled clinical performance of the STANDARD G6PD Test for G6PD

ROC curves (Supplementary Figure 3) and associated performance characteristics (Supplementary Table

235 7) show that the test performed well in detecting deficient individuals at the 30% activity threshold; the

area under the curve (AUC) was 0.998 and 0.997 for capillary and venous specimens, respectively. At the

237 70% threshold for intermediate females, AUC was 0.909 for capillary and 0.954 for venous specimens.

Table 3 summarizes the pooled diagnostic performance of the STANDARD G6PD Test for identifying

239 G6PD deficient males and females, and females with intermediate G6PD activity, by specimen type.

- 240 Overall, at the 30% threshold, the test had a sensitivity of 100% for both specimen types. The specificity
- 241 was 96.7% (95% CI 96.1%–97.2%) for combined venous and contrived specimens and 98.1% (95% CI
- 242 97.6%–98.5%) for capillary specimens. For females with intermediate G6PD activity levels, the
- sensitivity was 77.0% on capillary specimens (95% CI 66.8%–85.4%), 86.6% on venous specimens
- excluding contrived (95% CI 80.6%–91.3%), and 89.0% on venous specimens including contrived (95%
- 245 CI 85.4%–93.6%). Specificity was 92.8% for capillary specimens (95% CI 91.6%–93.9%), 94.9% for
- venous specimens without contrived (95% CI 93.3%–95.3%), and 93.9% for venous specimens including
- contrived (95% CI 92.8%–94.9%). Overall agreement was 94.8% for capillary and venous specimens, and
- 248 93.8% for venous and contrived specimens combined (Supplementary Table 6).
- All true deficient individuals were correctly identified by the STANDARD G6PD Test on both venous
- and capillary specimens and false normal results were only observed for females with intermediate G6PD
- activity (Figure 2; Table 4). On venous specimens, 10% (23/230) of intermediate females were
- 252 misclassified as normal, compared to 25% (20/87) on capillary specimen (Table 4). However, the

It is made available under a CC-BY-NC 4.0 International license .

- 253 majority (60%, 12/20) of these capillary discordant results were attributed to females with reference
- 254 G6PD activity greater than 60% and only two samples had G6PD activities between 40 and 50%.
- 255 (Supplementary Table 8; Table 5; Supplementary Figure 4). Negative predictive values for females with
- 256 >60% reference activity were 99.6% and 99.5% for capillary and venous specimens (without contrived),
- respectively (Table 3; Table 5). In contrast, false positive results (particularly for intermediates) occurred
- in 6% (120/1934) of G6PD normal females who were misclassified as intermediate and 1.5% (34/2178)
- 259 of G6PD normal males who were misclassified as deficient on capillary specimens.

Pooled clinical performance of the STANDARD G6PD Test for G6PD among *P. vivax* confirmed cases

- Among participants with *P. vivax* malaria, on both capillary and venous specimens, sensitivity was 100%
- 263 (95% CI 69.2%–100%) at the 30% threshold, with specificities of 99.0% (95% CI 97.4%–99.7%) and
- 264 97.7% (95% CI 95.6%–98.9%) for capillary and venous specimens, respectively (Table 3). However, it
- should be noted that this is based on a small number of deficient and intermediate cases (≤ 10) within this
- 266 population.

267 **Pooled clinical performance of the STANDARD G6PD Test for hemoglobin**

268 Linear regression of the STANDARD G6PD Test's hemoglobin result as compared to the hemoglobin

result on the reference CBC is shown in Supplementary Figure 5, by specimen type. R-squared

270 correlation values are 0.73 and 0.77 for capillary and venous specimens, respectively. Supplementary

- 271 Table 9 presents the agreement between the STANDARD G6PD Test's anemia classification on both
- 272 capillary and venous specimens as compared to the CBC results. Overall percent agreement between
- 273 methods was 90.3% (95% CI 89.0%–91.5%) for capillary specimens and 94.3% (95% CI 93.2%–95.2%)
- for venous specimens (excluding contrived). None of the participants with severe anemia (Hb <7.0 g/dL
- for children 6-59 months of age or <8.0 g/dL for all other groups, n=44) were misclassified as non or mild
- anemia on either capillary or venous blood.

277 Implications for malaria treatment

278 The STANDARD G6PD test results on capillary specimens were used to calculate the implications of the

- test performance on eligibility to different radical cure treatment options. Figures 3A and 3B illustrate a
- scenario where only daily primaquine radical cure regimen is available to males and females with G6PD
- activity greater than 30%. Based on the results of the STANDARD G6PD test, 94.8% (3993/4212) of the
- 282 participants, representing all G6PD normal and intermediate participants, would be eligible for standard
- 283 daily primaquine according to WHO guidelines and correctly provided primaquine based on the

It is made available under a CC-BY-NC 4.0 International license .

- concordance between the reference and POC test. Conversely, 5.2% (219/4212) would be excluded from
- standard primaquine treatment (Figure 3B). No G6PD deficient participants would be prescribed
- primaquine, but 1.8% (76/4212) males and females with intermediate and normal G6PD activity would be
- excluded from the daily treatment regimen (Figure 3B; Supplementary Table 10).
- Figures 3C and 3D illustrate a scenario where both daily primaquine and single dose tafenoquine are
- available and tafenoquine is only available to males and females with G6PD activity greater than 70%.
- Based on the POC STANDARD G6PD test results 87.1% (3668/4212) of participants in the study
- 291 population would be eligible for single dose radical cure (Figure 3C). One percent (43/4212) of the
- 292 population with G6PD activity \leq 70% would receive tafenoquine. These were 23 males and 20 females
- with G6PD activity between 30-70%, with a median G6PD activity of 63%. This analysis found that 7.7%
- of the population (168 males and 157 females) had a STANDARD G6PD Test result between 4 and 6 U/g
- Hb and would be eligible for standard daily primaquine all of these had G6PD activity > 30%. Of these,
- 296 6.5 % of the total population (153 males and 120 females) had a reference G6PD activity >70% and could
- have been treated with tafenoquine (Figure 3D; Supplementary Table 10).

298 **Discussion**

299 In this paper, performance data for the STANDARD G6PD POC test for G6PD deficiency, was

- 300 consolidated from multiple studies conducted on both capillary and venous specimens across seven
- 301 countries, representing diverse settings and use cases for G6PD testing.

302 Application of universal thresholds

303 Performance estimates for the STANDARD G6PD Test were calculated by applying a single set of 304 thresholds for G6PD deficiency and female intermediate activity in U/g Hb, as indicated by the 305 manufacturer's instructions for use. For the reference assay, site-specific adjusted male medians were 306 used to normalize results and establish 30% and 70% G6PD activity thresholds for defining deficient, 307 intermediate, and normal cases. The male median G6PD activity on the POC test was more consistent 308 across sites and specimen types—with the exception of one US site—in comparison to the reference 309 assay, which showed greater site-to-site variability. Inter-site variability in the male median G6PD activity as defined by spectrophotometry has been described previously,^{25,29} and is apparent even between 310 sites testing the same specimens.²² Site-to-site reproducibility of the STANDARD G6PD Test conducted 311 on commercially available controls also has decreased variability compared to the reference assay 312 conducted on the same control reagents in the same laboratories.³⁰ However, it is important to note with 313 314 respect to the medians and thresholds that the populations of the studies in this analysis largely comprised 315 of adults and children over the age of two. Only one study (in the United Kingdom) included few

It is made available under a CC-BY-NC 4.0 International license .

316 newborn samples. Using the STANDARD G6PD Test for newborn screening applications will require the use of higher G6PD threshold values to account for the higher G6PD activity among newborns.^{31–34} A 317 318 recent study conducted in Thailand with the STANDARD G6PD Test on 307 cord blood samples showed 319 good performance as long as the thresholds are adjusted to address the higher median G6PD activities in newborns.³⁵ A recent report suggests that malaria infection may also result in increased G6PD activity 320 when looking across all malaria in deficient and intermediate cases.³⁶ However, in our analysis, there was 321 322 no overall change in G6PD activity when comparing P. vivax-infected and uninfected males with normal 323 G6PD activity. The male median G6PD value on the STANDARD G6PD test is statistically consistent 324 across varied contexts and populations (aged two years and older), including in malaria-endemic settings, 325 with the exception of newborns.

326

327 Clinical implications for malaria case management

328 From a safety perspective, the sensitivity and negative predictive values of POC G6PD tests to identify 329 G6PD deficient and intermediate cases are critical to minimize adverse reactions to drugs that are 330 contraindicated in individuals with G6PD deficiency. This is particularly relevant for the test's use in 331 malaria case management, as standard 14-day primaguine regimens used for the radical cure of P. vivax malaria are not recommended for G6PD deficient males and females,^{37,38} and safety of higher dose 332 regimens among G6PD intermediate females is also a concern.³⁹ Additionally, tafenoquine is the first 333 drug to indicate a threshold G6PD activity (70%) on its label, above which data indicates that it is 334 considered safe to prescribe for radical cure.^{24,40} The calculations above suggest that the use of the 335 STANDARD G6PD Test at the point of care reduce risk of drug related hemolysis and so facilitate 336 337 appropriate provision of treatment, in line with WHO and global treatment guidelines.

The STANDARD G6PD Test showed good performance both on capillary and venous samples for G6PD deficiency when applying the manufacturer's universal thresholds, and no G6PD deficient cases were misclassified as normal, which ensures G6PD deficient malaria patients will receive correct primaquine regimens. In fact, the STANDARD G6PD Test tends toward overestimation of G6PD deficiency at the deficient and intermediate thresholds as compared to the reference assay (Supplementary Table 6).

343 The test's sensitivity decreased for females with intermediate activity. However, most of the false normal

results were attributed to females with G6PD activities >60%, (and all of whom had activities >40%),

345 which means that they are less likely to experience severe hemolysis as the potential for severe clinical

outcomes increases among those with more severe deficiency (i.e., a low percent G6PD activity). The

negative predictive values for females with G6PD reference activity >60% is good at 99.6% and 99.5%

It is made available under a CC-BY-NC 4.0 International license .

348 for both capillary and venous specimens, respectively. Among the almost 400 *P. vivax* cases included in

349 this analysis, none of the deficient or intermediate cases were incorrectly classified as normal by the

350 STANDARD G6PD Test. However, it should be noted that very few deficient and intermediate *P. vivax-*

351 positive cases were included in this sample.

352 Of note, challenges associated with false normal G6PD results are not limited to POC tests. For context, a

recent report from the College of American Pathologists (CAP) highlights challenges with the accurate

diagnosis of specimens with intermediate G6PD activity in current reference clinical laboratory testing.¹¹

355 Among laboratories participating in the CAP proficiency testing, 12.5% of those conducting quantitative

reference testing misclassified an intermediate specimen as normal, and 47.8% of those conducting

357 qualitative testing misclassified it as normal.¹¹ These findings suggest that misclassifications of G6PD

intermediate specimens are not unique to POC tests and that accurate classification of this group is a

359 challenge in clinical laboratory testing.

360 The specificity of a POC G6PD test is also important when considering performance, as such tests may

361 result in valuable treatment options being withheld from individuals without contraindications. Because

362 of the typically low prevalence of G6PD deficiency in many populations, any decrease in specificity will

363 significantly reduce the positive predictive power of the test with a significant proportion of G6PD

deficient and intermediate cases assigned by the POC test actually being G6PD normal individuals. This

365 was observed in the data presented here, where false deficient or intermediate misclassifications on the

366 STANDARD G6PD Test were more common than false normal results. Unpublished data from settings

367 where the STANDARD G6PD test has been scaled up and used outside the context of closely monitored

368 clinical studies indicates that the proportion of false deficient and intermediate cases appears to increase.

369 In the context of malaria, an overestimation of G6PD deficiency may prompt concerns about

370 unnecessarily restricting access to radical cure and higher levels of onward transmission and relapses.

371 Implications for malaria programs and future research

372 Results from this pooled performance analysis will inform future implementation and operational research

efforts for this test. One recent usability study conducted among intended test users from three high

374 malaria burden settings found that, with appropriate training, the test can be used in clinics managing

375 malaria cases.⁴¹ Recent studies also suggest that the incorporation of the test into *P. vivax* case

376 management in Brazil and Laos is cost effective; however, factors such as clinic case burdens and G6PD

deficiency prevalence are important considerations.^{42,43} Together, these performance, usability, and cost-

378 effectiveness findings suggest that the STANDARD G6PD Test can be used in malaria endemic settings

It is made available under a CC-BY-NC 4.0 International license .

- to support G6PD classification and significantly reduce the risk of drug induced hemolysis when
- 380 prescribing primaquine or tafenoquine, as well as other drugs such as rasburicase.⁴⁴

381 However, the positive predictive power of the test among this population, where a significant proportion

382 of individuals classified as G6PD deficient by the STANDARD test are in fact normal represents an

383 operational challenge in settings where confirmatory testing cannot be conducted. As is common for

384 many POC tests, confirmatory testing at a reference laboratory is also recommended if the test indicates a

positive result for the disease status.^{38,45} However, where a POC test has the most clinical utility, access to

reference confirmatory testing is unlikely. One must consider how to appropriately counsel patients

387 regarding the interpretation of their results.

388 This and the above limitations in test sensitivity need to be considered in the overall risk benefit

assessment of G6PD screening at the point of care, which should also take into consideration local G6PD

390 prevalence and vivax epidemiology as well as other drug eligibility criteria. Additional safety and

391 operational studies may be warranted. Future operational studies should investigate whether testing

392 strategies that involve repeat testing over two or three consecutive occasions can improve confirmation of

true G6PD deficient cases and the effective positive predictive value specially in settings with low

394 prevalence in G6PD deficiency. Additionally, given the extremely high negative predictive value (100%

for individuals >30% G6PD activity), exploring approaches to retain patients' G6PD test results could

reduce the need for repeat testing for the vast majority of the population, potentially leading to significant

397 cost savings. Finally, the feasibility of using the G6PD test at the community level where malaria care-

398 seeking often takes place will be critical to inform adoption strategies and scale.

399 Limitations

400 There are limitations to this analysis. The different studies contributing to this analysis were not originally

401 designed as a multi-center clinical study, and this pooled analysis was not prospectively planned for all

402 studies. However, the homogeneity in the designs of the included studies with regard to testing methods,

403 data collection, and reporting allows for combining of the data. Importantly, all included studies used one

404 of two compatible reference assays, the Trinity or the Point Scientific spectrophotometric reagent kits,

405 which are based on the same chemistry.⁴⁶ Further, a systematic literature search was not employed to

406 identify included studies. Lastly, our analysis includes fewer data generated from capillary specimens

407 than venous specimens. However, studies that evaluated test performance on capillary specimens included

408 several that were collected from POC settings in malaria endemic countries—Ethiopia, India, and

409 Brazil—and specifically clinics managing malaria cases.

It is made available under a CC-BY-NC 4.0 International license .

- 410 In summary, this pooled analysis supports the use of the STANDARD G6PD Test in near-patient settings
- 411 where rapid turnaround screening for G6PD status is needed to inform patient care and has previously
- 412 been unavailable. Operational and costing considerations should inform uptake of the test in specific
- 413 settings.⁴⁷

414

It is made available under a CC-BY-NC 4.0 International license .

415

416 **Funding**

- 417 The Brazil, Ethiopia, India, Thailand, UK, and US studies were funded by the United Kingdom's Foreign,
- 418 Commonwealth & Development Office (FCDO), grant number 204139 and, by the Bill & Melinda Gates
- 419 Foundation [OPP1107113, OPP1054404 and OPP1164105]. The FCDO and Bill & Melinda Gates
- 420 Foundation awards to PATH support the availability of point-of-care tests for G6PD deficiency.
- 421 GB, CSC, and FN work at the Shoklo Malaria Research Unit, part of the Mahidol Oxford University
- 422 Research Unit supported by the Wellcome Trust Mahidol Major Overseas Programme–Thailand Unit
- 423 (Grant Number 220211). For the purpose of Open Access, the authors have applied a CC BY public
- 424 copyright license to any author accepted manuscript version arising from this submission
- 425 RNP and the Bangladesh study were funded by the Wellcome Trust (Senior Fellowship in Clinical
- 426 Science, 200909), BL is funded by the Australian Department of Foreign Affairs and Trade, RNP is
- 427 funded by the Bill & Melinda Gates Foundation (OPP1054404 and OPP1164105).
- 428 MVGL and WMM are funded by Brazilian CNPq.
- 429 Under the grant conditions of the Gates Foundation, a Creative Commons Attribution 4.0 Generic License
- 430 has been assigned to the Author Accepted Manuscript version that might arise from this submission. The
- 431 findings and conclusions contained within are those of the authors and do not necessarily reflect the
- 432 positions of FCDO or the Gates Foundation. The funders had no role in study design, data collection and
- 433 analysis, decision to publish, or preparation of the manuscript.
- 434 Neither PATH, nor the co-authors have any financial interests in the commercial availability of any of the
- 435 products discussed in this article. All authors read the journal's authorship statement. All authors have
- 436 read the journal's policy on conflict of interest and do not have a conflict of interest to disclose

437 Tables

438 **Table 1. Summary of demographics.**

	Bangladesh ^a	Brazil ^b	Ethiopia	India	UK°	US (2021) ^c	Contrived Specimens ^c	US (2019) ^d	Thailand ^d	Total n (%)
Specimen type	Fresh venous K2EDTA	Fresh capillary and venous K2EDTA	Fresh capillary and venous K2EDTA	Fresh capillary and venous K2EDTA	Fresh venous K2EDTA	Fresh capillary and venous K2EDTA	Contrived venous	Fresh venous K2EDTA	Frozen venous K2EDTA	
Final Analytic population, n	108	1,736	1,015	951	167	623	95	174	150	5,019
Capillary Analytic population, n	N/A	1,693	1,009	889	N/A	621	N/A	N/A	N/A	4,212
Venous Analytic population, n	108	1,662	1,015	860	167	613	95	174	150	4,844
Sex, n (%)										
Female	81 (75.0)	948 (54.6)	476 (46.9)	345 (36.3)	87 (52.1)	309 (49.6)	90 (97.4)	73 (41.9)	108 (72.0)	2,517 (50.2)
Male	27 (25.0)	788 (45.4)	539 (53.1)	606 (63.7)	80 (47.9)	314 (50.4)	5 (5.3)	101 (58.1)	42 (28.0)	2,502 (49.8)
G6PD status, ^e n (%)		1		I						
Deficient < 30%	30 (27.8)	59 (3.4)	12 (1.2)	27 (2.8)	10 (6.0)	46 (7.4)	3 (3.2)	25 (14.4)	54 (36.0)	266 (5.3)
Intermediate 30%-70%	21 (19.4)	35 (2.0)	19 (1.8)	17 (1.8)	10 (6.0)	17 (2.7)	58 (61.1)	10 (5.7)	46 (30.7)	233 (4.6)
Normal >70%	57 (52.8)	1,642 (94.6)	984 (97.0)	907 (95.4)	147 (88.0)	560 (89.9)	34 (35.8)	139 (79.9)	50 (33.3)	4,520 (90.1)
Anemia status, ^f n (%)				<u>_</u>						
Non/mild	N/A	831 (47.9)	473 (46.6)	360 (37.9)	N/A	410 (65.8)	81 (85.3)	N/A	143 (95.3)	2,298 (45.8)

Moderate	N/A	83 (4.8)	1 (0.1)	91 (9.6)	N/A	23 (3.7)	11 (11.6)	N/A	7 (4.7)	216 (4.3)
Severe	N/A	10 (0.6)	0 (0)	30 (3.2)	N/A	1 (0.2)	3 (3.2)	N/A	0 (0)	44 (0.9)
Missing	108 (100.0)	812 (46.8)	541 (53.3)	470 (49.4)	167 (100.0)	189 (30.3)	0 (0)	174 (100.0)	0 (0)	2,461 (49.0)
Malaria result, ^g n (%)	Malaria result, ^g n (%)									
P. falciparum	N/A	12 (0.7)	27 (2.7)	29 (3.1)	N/A	N/A	N/A	N/A	N/A	68 (1.4)
P. vivax	N/A	199 (11.5)	0 (0.0)	242 (25.5)	N/A	N/A	N/A	N/A	N/A	441 (8.8)
P. falciparum/ P. vivax	N/A	40 (2.3)	0 (0.0)	1 (0.1)	N/A	N/A	N/A	N/A	N/A	41 (0.8)
Negative	N/A	1,484 (85.5)	988 (97.3)	679 (71.4)	N/A	N/A	N/A	N/A	N/A	3,151 (62.8)

a. Data published within Alam et al., 2018.

b .Data published within Zobrist et al., 2021.

439 440 441 442 443 444 445 446 447 c. Data published within Pal et al., 2021.

d. Data published within Pal et al., 2019.

e. G6PD status as determined by the spectrophotometric G6PD reference test on venous specimens, based on the specified activity thresholds.

f. Anemia status as measured by CBC in accordance with published clinically relevant Hb concentration thresholds from WHO. The non- and mild anemia categories were combined based on the

clinical significance of moderate or severe anemia diagnoses, consistent with the uses of other quantitative devices for the determination of Hb concentration at the point of care. Samples for which only

HemoCue Hb 201+ results were available are not included in this summary. Additionally, samples from Bangladesh were not included because of the limitations in the granularity of the data available.

g. Microscopy or rapid diagnostic test positive at recruitment.

448

449 Table 2. Adjusted G6PD normal male median (AMM) and analytical population male medians on the reference assay at the Porto Velho,

450 Brazil, and Kolkata, India, sites, by *P. vivax* malaria status.

	Porto Velho, Brazil	Kolkata, India
AMM	N=36	N=36
AMM Normal Males Median 100% (95% CI)	8.9 (8.6–9.4)	8.56 (7.9–9.1)
AMM <i>P. vivax</i> Normal Males Median 100% (95% CI)	8.7 (7.8 – 9.4)	8.21 (7.6 – 9.3)
P value	0.35	0.24
All Normal Males (analytical population)	N=368 (all) N=114 (P. vivax)	N=582 (all) N=197 (<i>P. vivax</i>)
All Normal Males Median 100% (95% CI)	9.1 (8.3 – 10.1)	8.7 (7.7 – 10.0)
All <i>P. vivax</i> Normal Males Median 100% (95% CI)	8.9 (8.1 – 9.8)	8.2 (7.3 – 9.4)
P value	0.08	0.001

451

452

- 453 Table 3. Summary diagnostic performance of the STANDARD G6PD Test for identifying G6PD deficient males and females
- 454 with intermediate G6PD activity, by specimen type, in all study participants and in *P. vivax* cases only.

Specimen	Cases			Performance for G6PD deficient males and females		Performance for G6PD intermediate females $(> 30, \le 70\%)$		3 x 3 overall percent agreement	Negative predictive value female > 60%
type	Deficient cases, n	Intermediate cases, n	Normal cases, n	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)	(95% CI)	(95% CI)
Capillary	143	79	3990	100.0 (97.5–100.0)	98.1 (97.6–98.5)	77.0 (66.8–85.4)	92.8 (91.6–93.9)	94.8 (94.1–95.5)	99.6 (99.1 – 99.8)
Venous (without contrived)	259	110	4380	100.0 (98.6–100.0)	97.6 (97.1–98.0)	86.6 (80.6–91.3)	94.4 (93.3–95.3)	94.8 (94.2–95.4)	99.5 (99.0 – 99.7)
Venous (with contrived)	262	152	4430	100.0 (98.6–100.0)	96.7 (96.1–97.2)	89.0 (85.4–93.6)	93.9 (92.8–94.9)	93.8 (93.1–94.5)	-
P. vivax-in	fected parti	cipants only	1		1	1	J		
Capillary	10	9	377	100.0 (69.2–100.0)	99.0 (97.4–99.7)	100.0 (39.8–100.0)	93.3 (86.7–97.3)	96.2 (93.8–97.9)	-
Venous	10	4	382	100.0 (69.2–100.0)	97.7 (95.6–98.9)	100.0 (39.8–100.0)	87.3 (79.2–93.0)	96.2 (93.8–97.9)	-

455

456

457 Table 4. 2 x 2 and 3 x 3 tables for males and female G6PD classifications respectively by the reference assay (columns) and by the

458 STANDARD G6PD test (rows). 30% and 70% normal G6PD activity thresholds were used to classify G6PD deficient and intermediate status,

459 respectively, with the reference spectrophotometric assay. Manufacturer thresholds on the STANDARD G6PD test were used to classify G6PD

460 deficient and intermediate status.

STANDARD G6PD Test Classification	Refer	Total					
Capillary: Male							
	Deficient	Nor	Total				
Deficient	134	3	164				
Normal	0	20	18	2018			
Total	134	20	48	2182			
Capillary: Female							
	Deficient	Intermediate	Normal	Total			
Deficient	9	30	19	58			
Intermediate	0	37	120	157			
Normal	0	20	1795	1815			
Total	9	87	1934	2030			
Venous*: Male							
	Deficient Normal Tota						
Deficient	205	205 34					
Normal	0	21	44	2144			
Total	205	21	78	2383			
Venous*: Female							
	Deficient	Intermediate	Normal	Total			
Deficient	57	111	7	175			
Intermediate	0	96	125	221			
Normal	0	23	2042	2065			
Total	57	230	2174	2461			

461 * Including contrived specimens

462

	% G6PD activity (reference assay)							
	≤ 70%	≤65%	≤ 60%	≤ 50%	≤40%			
Sensitivity (95% CI)	79.2	84.6	88.1	92.3	100.0			
	(69.7 – 86.8)	(74.7 – 91.8)	(77.8–94.7)	(79.1–98.4)	(83.9–100.0)			
Number of false normals	20	12	8	3	0			
Negative predictive power (95% CI)	98.9	99.3	99.6	99.8	100.0			
	(98.3–99.3)	(98.8–99.7)	(99.1–99.8)	(99.5–100.0)	(99.8–100.0)			

Table 5. Performance indicators applying the 6.0 U/g Hb threshold on the STANDARD G6PD Test for deficient and intermediate females

with G6PD activity levels between 0% and 40%, 50%, 60%, 65%, and 70% for capillary specimens.

465

463

It is made available under a CC-BY-NC 4.0 International license .

466 **References**

- Luzzatto L, Ally M, Notaro R. Glucose-6-phosphate dehydrogenase deficiency. *Blood*.
 2020;136(11):1225-1240. doi:10.1182/blood.2019000944
- 469 2. Luzzatto L, Arese P. Favism and Glucose-6-Phosphate Dehydrogenase Deficiency. *N Engl J Med.*470 2018;378(1):60-71. doi:10.1056/nejmra1708111
- Aydemir D, Dağlıoğlu G, Candevir A, et al. COVID-19 may enhance risk of thrombosis and
 hemolysis in the G6PD deficient patients. *Nucleosides Nucleotides Nucleic Acids*. 2021;40(5):505517. doi:10.1080/15257770.2021.1897457
- 474
 4. Elalfy M, Adly A, Eltonbary K, et al. Management of children with glucose-6-phosphate
 475
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 477
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 476
 47
- 5. Dean L, Kane M. *Rasburicase Therapy and G6PD and CYB5R Genotype*. National Center for
 Biotechnology Information (US); 2020. Accessed May 13, 2022.
 https://www.ncbi.nlm.nih.gov/books/NBK562585/
- 480
 6. Chu CS, Hwang J. Tafenoquine: a toxicity overview. *Expert Opin Drug Saf.* 2021;20(3):349-362.
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481
 481</l
- 482 7. Chu CS, Bancone G, Nosten F, White NJ, Luzzatto L. Primaquine-induced haemolysis in females
 483 heterozygous for G6PD deficiency. *Malar J.* 2018;17(1):101. doi:10.1186/s12936-018-2248-y
- 484
 485
 8. Cunningham AD, Hwang S, Mochly-Rosen D. G6PD deficiency and the need for a novel treatment to prevent kernicterus. *Clin Perinatol.* 2016;43(2):341-354. doi:10.1016/j.clp.2016.01.010
- 486
 487
 487
 487
 488
 488
 488
 488
 480
 480
 480
 480
 480
 480
 481
 481
 481
 482
 483
 483
 484
 484
 484
 484
 485
 485
 486
 486
 486
 487
 486
 487
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
- 489 10. Olusanya BO, Emokpae AA, Zamora TG, Slusher TM. Addressing the burden of neonatal
 490 hyperbilirubinaemia in countries with significant glucose-6-phosphate dehydrogenase deficiency.
 491 Acta Paediatr Oslo Nor 1992. 2014;103(11):1102-1109. doi:10.1111/apa.12735
- 492 11. Genzen JR, Nwosu A, Long T, Murphy H, Alter DN. An International Survey of Glucose-6 493 Phosphate Dehydrogenase Laboratory Reporting Practices. *Arch Pathol Lab Med*. Published online
 494 January 28, 2022. doi:10.5858/arpa.2021-0276-CP
- 495 12. Quantification of glucose-6-phosphate dehydrogenase activity by spectrophotometry: A systematic
 496 review and meta-analysis | PLOS Medicine. Accessed May 13, 2022.
 497 https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003084
- 498 13. Anderle A, Bancone G, Domingo GJ, Gerth-Guyette E, Pal S, Satyagraha AW. Point-of-Care Testing
 499 for G6PD Deficiency: Opportunities for Screening. *Int J Neonatal Screen*. 2018;4(4):34.
 500 doi:10.3390/ijns4040034
- World Health Organization. Guide to G6PD deficiency rapid diagnostic testing to support P. vivax
 radical cure. Published online 2018. Licence: CC BY-NC-SA 3.0 IGO.

- 15. Recht J, Ashley EA, White NJ. Use of primaquine and glucose-6-phosphate dehydrogenase
 deficiency testing: Divergent policies and practices in malaria endemic countries. *PLoS Negl Trop* Dis. 2018;12(4):e0006230. doi:10.1371/journal.pntd.0006230
- Ley B, Satyagraha AW, Rahmat H, et al. Performance of the Access Bio/CareStart rapid diagnostic
 test for the detection of glucose-6-phosphate dehydrogenase deficiency: A systematic review and
 meta-analysis. *PLOS Med.* 2019;16(12):e1002992. doi:10.1371/journal.pmed.1002992
- LaRue N, Kahn M, Murray M, et al. Comparison of Quantitative and Qualitative Tests for Glucose-6Phosphate Dehydrogenase Deficiency. *Am J Trop Med Hyg.* 2014;91(4):854-861.
 doi:10.4269/ajtmh.14-0194
- 512 18. Osorio L, Carter N, Arthur P, et al. Performance of BinaxNOW G6PD deficiency point-of-care
 513 diagnostic in P. vivax-infected subjects. *Am J Trop Med Hyg*. 2015;92(1):22-27.
 514 doi:10.4269/ajtmh.14-0298
- Pal S, Bansil P, Bancone G, et al. Evaluation of a Novel Quantitative Test for Glucose-6-Phosphate
 Dehydrogenase Deficiency: Bringing Quantitative Testing for Glucose-6-Phosphate Dehydrogenase
 Deficiency Closer to the Patient. *Am J Trop Med Hyg.* 2019;100(1):213-221. doi:10.4269/ajtmh.18 0612
- 20. Zobrist S, Brito M, Garbin E, et al. Evaluation of a point-of-care diagnostic to identify glucose-6phosphate dehydrogenase deficiency in Brazil. *PLoS Negl Trop Dis*. 2021;15(8):e0009649.
 doi:10.1371/journal.pntd.0009649
- Alam MS, Kibria MG, Jahan N, et al. Field evaluation of quantitative point of care diagnostics to
 measure glucose-6-phosphate dehydrogenase activity. *PLoS ONE*. 2018;13(11):e0206331.
 doi:10.1371/journal.pone.0206331
- Pal S, Myburgh J, Bansil P, et al. Reference and point-of-care testing for G6PD deficiency: Blood
 disorder interference, contrived specimens, and fingerstick equivalence and precision. *PLoS ONE*.
 2021;16(9):e0257560. doi:10.1371/journal.pone.0257560
- S28 23. Roper DR, De la Salle B, Soni V, Fletcher K, Green JA. Abrogation of red blood cell G6PD enzyme
 activity through Heat treatment: development of survey material for the UK NEQAS G6PD scheme.
 Int J Lab Hematol. 2017;39(3):308-316. doi:10.1111/ijlh.12627
- Lacerda MVG, Llanos-Cuentas A, Krudsood S, et al. Single-Dose Tafenoquine to Prevent Relapse of
 Plasmodium vivax Malaria. *N Engl J Med.* 2019;380(3):215-228. doi:10.1056/NEJMoa1710775
- 533 25. Calvaresi EC, Genzen JR. Evaluating Percentage-Based Reporting of Glucose-6-Phosphate
 534 Dehydrogenase (G6PD) Enzymatic Activity. *Am J Clin Pathol*. 2020;154(2):248-254.
 535 doi:10.1093/ajcp/aqaa040
- Ley B, Bancone G, von Seidlein L, et al. Methods for the field evaluation of quantitative G6PD
 diagnostics: a review. *Malar J*. 2017;16(1):361. doi:10.1186/s12936-017-2017-3
- 538 27. Domingo GJ, Satyagraha AW, Anvikar A, et al. G6PD testing in support of treatment and elimination
 539 of malaria: recommendations for evaluation of G6PD tests. *Malar J*. 2013;12(1):391.
 540 doi:10.1186/1475-2875-12-391


- 541 28. World Health Organization. *Haemoglobin Concentrations for the Diagnosis of Anaemia and*542 *Assessment of Severity*. World Health Organization; 2011. Accessed March 15, 2021.
 543 https://www.who.int/vmnis/indicators/haemoglobin.pdf
- 544 29. Pfeffer DA, Ley B, Howes RE, et al. Quantification of glucose-6-phosphate dehydrogenase activity
 545 by spectrophotometry: A systematic review and meta-analysis. *PLoS Med.* 2020;17(5):e1003084.
 546 doi:10.1371/journal.pmed.1003084
- 547 30. Ley B, Winasti Satyagraha A, Kibria MG, et al. Repeatability and reproducibility of a handheld
 548 quantitative G6PD diagnostic. *PLoS Negl Trop Dis*. 2022;16(2):e0010174.
 549 doi:10.1371/journal.pntd.0010174
- 550 31. Fu C, Luo S, Li Q, et al. Newborn screening of glucose-6-phosphate dehydrogenase deficiency in
 551 Guangxi, China: determination of optimal cutoff value to identify heterozygous female neonates. *Sci* 552 *Rep.* 2018;8(1):833. doi:10.1038/s41598-017-17667-6
- 32. Riskin A, Gery N, Kugelman A, Hemo M, Spevak I, Bader D. Glucose-6-phosphate dehydrogenase
 deficiency and borderline deficiency: association with neonatal hyperbilirubinemia. *J Pediatr*.
 2012;161(2):191-6.e1. doi:10.1016/j.jpeds.2012.02.018
- 33. Doherty AN, Kring EA, Posey YF, Maisels MJ. Glucose-6-phosphate dehydrogenase activity levels
 in white newborn infants. *J Pediatr*. 2014;164(6):1416-1420. doi:10.1016/j.jpeds.2014.02.029
- 558 34. Kaplan M, Abramov A. Neonatal Hyperbilirubinemia Associated With Glucose-6-Phosphate
 559 Dehydrogenase Deficiency in Sephardic-Jewish Neonates: Incidence, Severity, and the Effect of
 560 Phototherapy. *Pediatrics*. 1992;90(3):401-405. doi:10.1542/peds.90.3.401
- 35. Bancone G, Gilder ME, Win E, et al. Quantitative G6PD point-of-care test can be used reliably on
 cord blood to identify male and female newborns at increased risk of neonatal hyperbilirubinaemia: a
 mixed method study. *medRxiv*. doi:10.1101/2022.07.03.22277173
- 564 36. Ley B, Alam MS, Satyagraha AW, et al. Variation in Glucose-6-Phosphate Dehydrogenase activity
 565 following acute malaria. *PLoS Negl Trop Dis*. 2022;16(5):e0010406.
 566 doi:10.1371/journal.pntd.0010406
- Milligan R, Daher A, Villanueva G, Bergman H, Graves PM. Primaquine alternative dosing
 schedules for preventing malaria relapse in people with Plasmodium vivax. *Cochrane Database Syst Rev.* 2020;8:CD012656. doi:10.1002/14651858.CD012656.pub3
- Step 38. Chu CS, Bancone G, Kelley M, et al. Optimizing G6PD testing for Plasmodium vivax case
 management and beyond: why sex, counseling, and community engagement matter. *Wellcome Open Res.* 2020;5:21. doi:10.12688/wellcomeopenres.15700.2
- Taylor WRJ, Thriemer K, Seidlein L von, et al. Short-course primaquine for the radical cure of
 Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. *The Lancet*. 2019;394(10202):929-938. doi:10.1016/S0140-6736(19)31285-1
- 40. Llanos-Cuentas A, Lacerda MVG, Hien TT, et al. Tafenoquine versus Primaquine to Prevent Relapse
 of Plasmodium vivax Malaria. *N Engl J Med.* 2019;380(3):229-241. doi:10.1056/NEJMoa1802537

It is made available under a CC-BY-NC 4.0 International license .

- 41. Gerth-Guyette E, Adissu W, Brito M, et al. Usability of a point-of-care diagnostic to identify glucose6-phosphate dehydrogenase deficiency: a multi-country assessment of test label comprehension and
 results interpretation. *Malar J*. 2021;20(1):307. doi:10.1186/s12936-021-03803-1
- 42. Aung YN, Tun STT, Vanisaveth V, Chindavongsa K, Kanya L. Cost-effectiveness analysis of G6PD
 diagnostic test for Plasmodium vivax radical cure in Lao PDR: An economic modelling study. *PloS One*. 2022;17(4):e0267193. doi:10.1371/journal.pone.0267193
- 43. Brito-Sousa JD, Peixoto HM, Devine A, et al. Real-life quantitative G6PD screening in Plasmodium
 vivax patients in the Brazilian Amazon: A cost-effectiveness analysis. *PLoS Negl Trop Dis*.
 2022;16(3):e0010325. doi:10.1371/journal.pntd.0010325
- 44. Ganapathi M, Campbell P, Ofori K, Aggarwal V, Francis RO, Kratz A. Impact of pre-emptive rapid
 testing for glucose-6-phosphate dehydrogenase deficiency prior to rasburicase administration at a
 tertiary care centre: A retrospective study. *Br J Clin Pharmacol*. Published online April 14, 2022.
 doi:10.1111/bcp.15353
- 591 45. Domingo GJ, Advani N, Satyagraha AW, et al. Addressing the gender-knowledge gap in glucose-6592 phosphate dehydrogenase deficiency: challenges and opportunities. *Int Health*. 2019;11(1):7-14.
 593 doi:10.1093/inthealth/ihy060
- 46. Alam MS, Kibria MG, Jahan N, Price RN, Ley B. Spectrophotometry assays to determine G6PD
 activity from Trinity Biotech and Pointe Scientific G6PD show good correlation. *BMC Res Notes*.
 2018;11(1):855. doi:10.1186/s13104-018-3964-7
- 597 47. Engel N, Ghergu C, Matin MA, et al. Implementing radical cure diagnostics for malaria: user
 598 perspectives on G6PD testing in Bangladesh. *Malar J*. 2021;20(1):217. doi:10.1186/s12936-021599 03743-w

600

It is made available under a CC-BY-NC 4.0 International license .










Figure 2. G6PD activity classification of the STANDARD G6PD and reference assays for A) males and B) females. G6PD status classification measured by the STANDARD G6PD test is shown on the X-axis, for capillary (grey) and venous (black) specimens, respectively. Results are plotted by the reference G6PD percent activity (Y-axis). Shaded areas correspond to true G6PD normal (green), intermediate (yellow), and deficient (red) status classifications on the reference assay.








It is made available under a CC-BY-NC 4.0 International license .



Supplementary Figure 4. Distribution of false normal capillary results, by study.*



* Red shaded areas correspond to deficient (\leq 30%) reference assay values, and yellow shaded areas correspond to intermediate (30-70%) reference assay values, with darker shading at lower percent activity.

